Our Team

Managing Director & Founder

Ian Dixon

PhD, MBA, MAICD

Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.

Ian has been successful in translating technology challenges into valuable businesses and respected intellectual property.

Ian is a co-inventor of Exopharm’s LEAP manufacturing technology and a co-inventor of Fortrexo, part of Exopharm’s EEV pipeline.

Ian brings to Exopharm an extensive technical, commercial and entrepreneurial background.

Before founding Exopharm in 2013, Ian co-founded Cynata Inc, the owner of the Cymerus stem cell technology now being commercialised by ASX-listed clinical-stage Cynata Therapeutics Ltd (ASX:CYP).

He is also non-executive director of NYRADA Inc. (ASX:NYR), co-inventor of Nyrada PCSK9 inhibitor drug NYX-330, and founder and investor of Cardio Therapeutics Pty Ltd.

Ian was previously a founding director of Sydney-based Noxopharm Ltd (ASX:NOX) and non-executive director of Melbourne unlisted company Cell Therapies Pty Ltd.

Chief Operating Officer

Daisy Scarborough

Daisy is an MBA graduate from Melbourne Business School with over 20 years experience leading high performing teams within large organisations.

Daisy embarked her career journey as an Accountant for Angus & Robertson (pre-Kindle days!) before embracing a 10-year career at The Walt Disney Company. Accountant transformed into Change Leader and Special Projects Manager at Disney led to Daisy embedding that Disney magic throughout several mergers and acquisitions across the International markets undertaken by Disney at the time.

Seeking to work for an Australian company and apply her business school knowledge, Daisy spent 7 years at Origin Energy in the highly regulated and competitive Energy Industry leading Customer Operations for the Retail business.

Daisy’s role as Chief of Staff and Head of the Corporate Operations Group at Exopharm is to enable growth, drive performance outcomes and to ensure Exopharm is seen as a leader in exosome medicine. Daisy is responsible for Business Services, Communications, Human Resources, Legal & Intellectual Property.

Chief Technology Officer

Michael West

Mike holds a PhD in Chemistry and graduate qualifications in law and management. He brings 23 years of industry experience in drug development of both pre-clinical and clinical assets. Mike has worked in big-Pharma and has had C-suite roles in several biotechnology companies, bringing a wealth of experience in technology management to Exopharm.

Mike will drive technology and drug development at Exopharm, to reinforce our world leading reputation. Mike is also assisting in the selection of the pipeline products and will contribute to the development programs of those products.

President - International

David Oxley

David Oxley brings extensive commercial experience in life sciences, with a focus in novel technologies in the biotech and life sciences sectors.  He has a proven track record of commercial success, including prosecuting complex, cross-border licensing constructs, inclusive of non-dilutive capital raising, world-wide commercial P&L management, and new product launch experience.

Within the biotech sector, his most recent experience includes service as senior vice president of business development and licensing for Melbourne-based, cellular medicines leader, Mesoblast, where he continues his service as a consultant.

Mr. Oxley’s previous assignments include chief executive officer of a Beijing-based cellular medicines company, and senior vice president of emerging markets and general manager of China for a California-based regenerative medicines company.

Prior to his tenure within the biotech sector, David served a combined eighteen years in executive leadership positions in the life sciences arena, including head of global sales and marketing and head of global government relations for medical devices companies, health-care capital markets management for a leading U.S. bank, healthcare policy advocacy before the U.S. Food and Drug Administration in addition to service as legislative staff for a Member of the United States Congress.

Beyond his corporate management experience, David served on the boards of a privately held antibody-based medical device company in the U.S. and a not-for-profit foundation that is focused on infectious diseases in Africa.

David completed his bachelors’ studies in history at Portland State University and his master’s studies in government and public health at Johns Hopkins University in the U.S.

Senior Vice President - Finance

Johannes Mühl

Johannes is based in Zurich, Switzerland and has a vast network in the life-science industry and is also a successful private investor in the biotech sector.

Johannes has a PhD from Edinburgh Napier University and is a Fellow of the Institute of Public Accountants (FIPA) Australia. Johannes also has a Diploma of International Business Administration from Furtwangen University and is currently studying towards a Master of Public Health at the University of Zurich.

Johannes brings with him a wealth of transferable skills – analytical precision, deep understanding of Finance and Accounting across continents, deal making, and thorough knowledge of the gene therapeutics and diagnostics market.

At Exopharm Johannes is building the profile of Exopharm in the investment community and helping to shape Exopharm’s pipeline products and associated strategy and finance plan.

Previously, Johannes was International Head of Finance and Business Insights at Myriad Genetics where he co-led the organisation through a successful transformation with growth of top and bottom line. He has over 15 years of life-science industry finance experience with roles in Pfizer and Zimmer Biomet.